Platinum Investment Management’s Exagen XGN Stock Holding History

Platinum Investment Management’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-264,130	Closed	-$634K	–	155
2022 Q4	$634K	Sell	264,130 -86,941	-25%	-$223K	0.02%	103
2022 Q3	$951K	Sell	351,071 -48,929	-12%	-$273K	0.04%	96
2022 Q2	$2.3M	Hold	400,000	–	–	0.09%	77
2022 Q1	$3.21M	Hold	400,000	–	–	0.1%	67
2021 Q4	$4.65M	Hold	400,000	–	–	0.13%	65
2021 Q3	$5.44M	Hold	400,000	–	–	0.15%	61
2021 Q2	$6M	Hold	400,000	–	–	0.14%	61
2021 Q1	$7M	Buy	+400,000	New	+$7.13M	0.16%	45

Other funds holding XGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Platinum Investment Management's XGN Position: Q1 2023 in Review

Platinum Investment Management sold out of Exagen (XGN) in Q1 2023, closing a stake of 264,130 shares — an estimated $634K sold.

Platinum Investment Management first reported a position in XGN in Q1 2021 and held it in 8 quarters. The position peaked at $7M in Q1 2021. 28 funds tracked by Wall St. Rank hold XGN as of Q1 2023.

Platinum Investment Management reported no remaining Exagen position as of Q1 2023 after selling out during the quarter.
Platinum Investment Management sold 264,130 Exagen shares in Q1 2023, an estimated $634K.
Platinum Investment Management first reported a position in Exagen in Q1 2021 and held it in 8 quarters.
Platinum Investment Management's Exagen position peaked at $7M in Q1 2021.
28 funds tracked by Wall St. Rank held Exagen as of Q1 2023.

Based on Platinum Investment Management's 13F filing for Q1 2023, filed 12 May 2023.